Paul Forsyth

@pharmacisthf.bsky.social

Pharmacist, FRPharmS (Consultant), Equal parts cardiology 🫀, philosophical pharmacy angst 💊💭🤯, and mid-40s life stuff 👧👧👧👩‍💼🐕‍🦺 #HeartFailure #PharmSky #CardioSky 🏴󠁧󠁢󠁳󠁣󠁴󠁿☘️ https://scholar.google.com/citations?user=yrHCleUAAAAJ&hl=en

My UK chief pharmaceutical officers colleagues & I have provided advice to help pharmacy professionals wanting to take part in the debate on assisted dying. This follows similar advice recently issued to doctors and nurses: www.gov.uk/government/p...

Assisted dying bill debate: advice to pharmacy professionals

The UK chief pharmaceutical officers have given advice to help pharmacists and pharmacy technicians wanting to take part in the assisted dying debate.

gov.uk

Before the porridge moralists jump in, pls note, that the report found poorer households would have to *double* their food spend to be able to eat a healthy diet. Poverty sickens society. Raise benefits & minimum wage, for cost effective benefits to society. www.theguardian.com/politics/202...

UK’s unhealthy food habits cost £268bn a year, report finds

Exclusive: Food, Farming and Countryside Commission added up cost to NHS and economy of diet-linked disease

theguardian.com

BPROAD trial: “Among patients with T2 diabetes, the incidence of major CVD events was significantly lower with intensive treatment targeting a systolic blood pressure of <120 mm Hg than with standard treatment targeting a systolic blood pressure of <140 mm Hg” www.nejm.org/doi/full/10....

Intensive Blood-Pressure Control in Patients with Type 2 Diabetes | NEJM

Effective targets for systolic blood-pressure control in patients with type 2 diabetes are unclear. We enrolled patients 50 years of age or older with type 2 diabetes, elevated systolic blood press...

nejm.org

SUMMIT trial: “Treatment with tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure than placebo and improved health status in patients with heart failure with preserved ejection fraction and obesity” www.nejm.org/doi/full/10....

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | NEJM

Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor...

nejm.org